The CADMUS trial – Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer
| Autor: | R. Scott, Charles Jameson, Peter Frinking, Manit Arya, Peter Acher, Hashim U. Ahmed, Chris Brew Graves, Mark Emberton, Sidath H. Liyanage, Alex Freeman, Gabriel Constantinescu, Susan C. Charman, Sanjeev Madaan, Jan van der Meulen, Bina Shah, Alistair Grey, Navin Ramachandran |
|---|---|
| Přispěvatelé: | Wellcome Trust |
| Rok vydání: | 2018 |
| Předmět: |
Image-Guided Biopsy
Male medicine.medical_specialty Prostate biopsy 030232 urology & nephrology Adenocarcinoma Cohort Studies 03 medical and health sciences Prostate cancer 0302 clinical medicine Prostate Biopsy Humans Medicine Pharmacology (medical) Prospective Studies TRUS Cadmus General Clinical Medicine Ultrasonography Multi parametric medicine.diagnostic_test Multiparametric MRI Targeted prostate biopsy business.industry Ultrasound Prostatic Neoplasms 11 Medical And Health Sciences General Medicine medicine.disease Magnetic Resonance Imaging medicine.anatomical_structure Multiparametric ultrasound 030220 oncology & carcinogenesis Cohort Public Health Radiology Neoplasm Grading business |
| Zdroj: | Contemporary Clinical Trials. 66:86-92 |
| ISSN: | 1551-7144 3854-1912 |
| Popis: | OBJECTIVE: To compare the proportion of clinically significant prostate cancers (PCa) found in lesions detected by multiparametric MRI (mpMRI) with that found in lesions detected by multiparametric ultrasound (mpUSS), in men at risk. PATIENTS AND METHODS: CADMUS (Cancer Detection by Multiparametric Ultrasound of the prostate) is a prospective, multi-centre paired cohort diagnostic utility study with built-in randomisation of order of biopsies. The trial is registered ISRCTN38541912. All patients will undergo the index test under evaluation (mpUSS±biopsies), as well as the standard test (mpMRI±biopsies). Eligible men will be those at risk of harbouring prostate cancer usually recommended for prostate biopsy, either for the first time or as a repeat, who have not had any prior treatment for prostate cancer. Men in need of repeat biopsy will include those with prior negative results but ongoing suspicion, and those with an existing prostate cancer diagnosis but a need for accurate risk stratification. Both scans will be reported blind to the results of the other and the order in which the targeted biopsies derived from the two different imaging modalities are taken will be randomised. Comparison will be drawn between biopsy results of lesions detected by mpUSS with those lesions detected by mpMRI. Agreement over position between the two imaging modalities will be studied. DISCUSSION: CADMUS will provide level one evidence on the performance of mpUSS derived targeted biopsies in the identification of clinically significant prostate cancer in comparison to mpMRI targeted biopsies. Recruitment is underway and expected to complete in 2018. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect